4-in-1 Tests in Urgent Care: Cost, Accuracy, & Reimbursement

Are 4-in-1 Home Tests Worth It for Urgent Care? Balancing Cost, Accuracy, and Reimbursement

Respiratory season puts pressure on urgent care practices to deliver fast, accurate testing while managing supply costs. When a four-in-one home test for COVID-19, influenza A, influenza B, and RSV costs less than a professional point-of-care test, the choice may appear straightforward.

But the lowest-priced kit is not always the lowest-cost option for the practice.

An urgent care considering a home test (or any point of care test) must evaluate more than the purchase price. The decision also involves the product’s intended use, clinical performance, CLIA requirements, payer coverage, and whether the practice would give up reimbursement available for a professional test.

The question is not simply “How much does the test cost?” It should be “What is the overall clinical and financial impact of the testing model?”

What is a 4-in-1 respiratory test?

A four-in-one respiratory test checks for four targets:

1. SARS-CoV-2, the virus that causes COVID-19
2. Influenza A
3. Influenza B
4. Respiratory syncytial virus, or RSV

Both consumer home tests and professional point-of-care respiratory tests are available. Some use antigen technology, while other professional tests use molecular methods.

The exact product matters. A manufacturer may offer home and professional versions with similar names but different instructions and intended uses. Before purchasing or implementing a test, the practice should verify the exact product’s labeling, FDA status, applicable CLIA classification, and payer requirements.

For example, the FDA lists distinct home and professional versions of a COVID-19, flu A/B, and RSV test. One product’s status should not be assumed to apply to the other. www.accessdata.fda.gov

Why an urgent care might consider lower-cost home tests

The appeal is understandable. A practice may compare a consumer test with its current professional test and see an opportunity to reduce supply expenses during a high-volume respiratory season.

Lower purchase cost

If a home test costs substantially less per kit, the potential savings can seem significant when multiplied across hundreds or thousands of respiratory visits.

For an urgent care with multiple locations, even a small per-test difference may appear to represent a meaningful reduction in supply spending.

One test for multiple viruses

A four-target test can provide results for COVID-19, influenza A, influenza B, and RSV from one specimen. Depending on the practice’s current process, that could simplify inventory or reduce the need for multiple separate test kits.

Familiarity and convenience

Staff and patients may already be familiar with rapid home tests. A visually read test may also appear simpler than a platform that requires an analyzer, equipment maintenance, or service agreements.

These are reasonable operational considerations—but they do not establish that a home-use product is appropriate for clinic staff to perform or that it will be reimbursed.

The biggest financial risk: Saving on the kit but losing reimbursement

The purchase price is only one part of the calculation. A professional point-of-care test may generate separate reimbursement when it is medically necessary, properly performed and billed, and covered under the patient’s plan and the practice’s contract.

If a practice switches to a home-use product without confirming whether the intended clinic workflow and payer billing are permitted, it may:

• Lose reimbursement it otherwise would have received
• Experience claim denials or payment delays
• Face repayment requests following an audit
• Absorb the entire cost of the test
• Spend more on billing follow-up and appeals
• Create patient billing concerns if charges were not properly disclosed or permitted

Some urgent care contracts, however, use a case rate that includes certain laboratory services. In that situation, separate test reimbursement may not be part of the financial picture, and reducing an allowable supply cost may have greater value.

The right answer depends on the practice’s payer mix, contracts, product, and workflow.

Example: When the cheaper kit costs the practice more

The following figures are illustrative only. They are not actual payer rates or an indication that a particular home test may be used or billed in a clinic.

Assume a practice is comparing two models for 1,000 medically appropriate respiratory tests:

• Kit cost per test: $25 professional test vs. $10 home-test scenario
• Total kit cost for 1,000 tests: $25,000 vs. $10,000
• Actual separate payer collections per test: $45 vs. $0
• Total separate test collections: $45,000 vs. $0
• Collections minus kit cost: $20,000 vs. –$10,000

In this example, the home-test scenario saves $15,000 in kit purchases but gives up $45,000 in separate collections. The resulting difference is $30,000 before accounting for labor, quality control, analyzer costs, repeat testing, billing expenses, and other operating costs.

The example assumes the professional test is appropriately performed and separately paid for every test. Actual payment rates, denials, patient collections, and contract terms will vary. It also assumes the home-test workflow is permissible; a favorable financial calculation does not establish that it is.

What if testing is included in a case rate?

If both tests are included in the same case rate and neither generates additional payment, the comparison changes:

• Kit cost per test: $25 professional test vs. $10 home-test scenario
• Separate test payment: $0 vs. $0
• Kit cost difference per test: $15 less for the home-test scenario

In that scenario, the lower-cost product could reduce supply expense if the product and proposed workflow are permitted and clinically appropriate. Other differences—such as staff time, repeat testing, and performance—still matter.

Operator takeaway: Review reimbursement by payer and contract before making a purchasing decision. Do not assume all respiratory tests are paid separately—or that all are included in the visit.

Can an urgent care use a home test in the clinic?

This is a critical question to resolve before ordering or using the tests.

A product cleared or authorized for home use has specific instructions about its intended use, including who performs the test and how it is used. A clinic’s ability to use that product depends on the exact product labeling, the proposed workflow, and applicable federal and state requirements.

CDC guidance on COVID-19 testing states that when a self-test is performed or interpreted by someone other than the patient or their parent or guardian, it is no longer treated as a self-test for CLIA purposes. The testing site needs an appropriate CLIA certificate, and CDC directs point-of-care sites to use tests authorized for point-of-care use and follow the manufacturer’s instructions. www.cdc.gov

There is also a distinction between a patient independently performing and reading their own home test and clinic personnel performing or interpreting it. CMS guidance discusses this distinction for COVID-19 OTC self-testing. The specific circumstances and test instructions matter. www.cms.gov

Practical step: Have your laboratory director or compliance lead review the exact product and proposed workflow. A CLIA Certificate of Waiver does not, by itself, establish that every home-use product can be used in any manner the clinic chooses.

Does CLIA-waived mean the test is reimbursable?

No. CLIA status and payer reimbursement are separate questions.

CLIA addresses laboratory testing requirements and the complexity of tests that a certified facility may perform. Payer coverage and reimbursement depend on additional factors, which may include:

• The exact test and method
• Medical necessity
• The patient’s coverage and benefits
• The payer’s laboratory policy
• The practice’s contract and fee schedule
• The appropriate code and any required modifier
• The clinic’s CLIA information
• Documentation and claim submission requirements

A test may meet applicable laboratory requirements and still be denied or bundled under a payer’s policy. Likewise, a code appearing on a fee schedule does not by itself establish that a particular product, use, or claim qualifies for payment.

Pros and cons of considering home tests in urgent care

Potential advantages

• Lower purchase price for some products
• One test may cover four respiratory targets
• May reduce supply expense under an inclusive case rate
• Potentially simple inventory and workflow
• Could support selected patient self-testing workflows
• May provide a lower-cost option for some patient needs

Potential disadvantages

• Separate payer reimbursement may be unavailable or uncertain
• Home-use labeling may not support the proposed clinic workflow
• Incorrect use or billing may create compliance and repayment risk
• Clinical performance may differ from the current professional test
• Negative results may require follow-up or additional testing
• Duplicate testing, labor, and administrative costs can offset kit savings

The balance will differ by location and payer. An urgent care should evaluate both the clinical and financial implications before changing its standard testing approach.

Clinical considerations: Lower cost cannot be the only factor

A testing product should support the clinic’s standard of care and the provider’s clinical decision-making.

Compare test performance

Review the manufacturer’s performance information for each virus and relevant patient population. Consider:

• Sensitivity and specificity for each target
• The specimen type and collection process
• The authorized age range
• The symptom window
• Performance in the populations your clinic commonly serves
• Whether a negative result may require further evaluation or testing

Many home combination tests use antigen technology. A negative antigen result does not necessarily rule out infection. CDC recommends molecular testing for symptomatic patients with suspected influenza and/or COVID-19 when testing is appropriate to help guide timely treatment. www.cdc.gov

Consider the cost of repeat testing

A lower-priced test may not save money if patients frequently require an additional test, longer visits, or follow-up because the first result does not adequately answer the clinical question.

The opposite can also be true: a more expensive test may not be necessary for every patient. Providers should select testing based on medical necessity and whether the result will influence care.

Protect the treatment window

Patients at higher risk for severe illness may benefit from prompt evaluation and timely treatment. A negative home antigen result should not automatically end the assessment when clinical suspicion remains high. www.cdc.gov

How reliable are 4-in-1 home tests compared with traditional CLIA-waived clinic tests?

When comparing a lower-cost 4-in-1 home test with a traditional urgent care test, the most useful question is: How does this specific product perform for each virus in the patients we serve?

The answer is not as simple as “clinic tests are more accurate” or “home tests are just as good.” A CLIA-waived clinic test may use either antigen or molecular technology, and individual products can perform differently. CLIA-waived status indicates the test’s regulatory complexity category; it is not an accuracy rating.

Sensitivity and specificity: What do they mean?

• Sensitivity: How often a test identifies an infection when it is present, compared with the reference method. Lower sensitivity means more infections may be missed, producing false-negative results.
• Specificity: How often a test correctly gives a negative result when the infection is absent, compared with the reference method. Lower specificity means more false-positive results may occur.
• Reliability in practice: How consistently the test performs when used as directed. Sample collection, timing, storage, instructions, and result interpretation can affect performance.

Manufacturers may report positive percent agreement (PPA) and negative percent agreement (NPA) rather than sensitivity and specificity. These describe agreement with the comparison test used in the study. Review the study design and reference method before treating the terms as interchangeable.

Home antigen tests vs. clinic antigen and molecular tests

CDC notes that molecular tests have higher sensitivity than antigen tests for detecting respiratory viruses in respiratory specimens. However, that does not mean every molecular product performs identically or that a professional antigen test is automatically more sensitive than a home antigen test. www.cdc.gov

Why RSV deserves particular attention

RSV test performance can vary by patient age and testing method. A systematic review of RSV testing in adults found that rapid antigen tests were less sensitive than RT-PCR in the studies reviewed. Its pooled estimate should not be applied to every current 4-in-1 product, but it illustrates why practices should look carefully at RSV performance—particularly when caring for older adults. pubmed.ncbi.nlm.nih.gov

For an urgent care serving both children and adults, it is worth asking:

• Does the manufacturer report RSV performance separately for adults and children?
• How many positive RSV samples were included in each group?
• Is the test’s performance adequate for the clinical decisions the practice expects to make?
• When would a negative antigen result lead the provider to consider molecular testing or additional evaluation?

A high-specificity test can still miss infections

A test can be good at avoiding false positives and still miss a meaningful number of true infections.

For example, imagine a test with 90% sensitivity and 98% specificity. Among 100 people who truly have the infection, the test would be expected to identify about 90 and miss about 10. Among 100 people who do not have it, it would be expected to produce approximately two false positives.

These are illustrative numbers, not performance claims for a particular test. In practice, the probability that an individual result is correct also depends on factors such as how common the virus is in the community, symptoms, and timing. A positive result may be more likely to be false when the infection is uncommon; a negative result can be less reassuring when the infection is widespread and clinical suspicion is high.

Compare the actual tests—not just the marketing claims

Before replacing a professional test with a lower-cost alternative, request the current instructions for use and performance data for both exact products. Compare:

1. Results by target: COVID-19, influenza A, influenza B, and RSV may have different sensitivity and specificity or PPA and NPA.
2. Reference method: Was each test compared with PCR or another method?
3. Sample size and confidence intervals: Results based on a small number of positive samples are less precise.
4. Patient population: Were adults, children, and older adults represented?
5. Symptom timing: Were samples collected within the same number of days after symptoms began?
6. Specimen and collection method: Was the sample self-collected or collected by trained staff?
7. Setting and workflow: Were results produced in a home-use study, a professional setting, or both?
8. Head-to-head evidence: Were the products tested in the same patients under comparable conditions?

Avoid declaring one product superior based only on percentages from separate manufacturer studies. Differences in study populations, circulating viruses, timing, and sample sizes can affect the results.

What does this mean for the financial decision?

A lower-cost test may have an acceptable clinical role, but its sticker price should be evaluated alongside its performance and the consequences of a missed result. Depending on the situation, those consequences may include additional testing, a return visit, delayed treatment, or added staff time.

Likewise, a more expensive molecular test may be appropriate for some patients but unnecessary for others. The provider’s choice should reflect the patient’s risk, clinical presentation, and whether the result will change care.

The operational takeaway: Compare the exact products on clinical performance, permitted use, total cost, and payer reimbursement. A lower-cost test is a good value only when it supports appropriate care and fits the practice’s compliant testing and billing workflow.

How to calculate the true cost of respiratory testing

Before switching products, compare your current model with the proposed alternative using actual collected revenue, not just billed charges.

Step 1: Calculate the complete cost per test

Include:

• Test kit and collection supplies
• Analyzer purchase, lease, maintenance, or service costs, if applicable
• Quality-control materials
• Staff time
• Shipping, storage, and expiration-related waste
• Repeat or confirmatory testing
• Billing and denial-management costs

Step 2: Determine actual payment by payer

Review recent claims and contracts to determine:

• Which payers reimburse the current test separately?
• What is the actual allowed amount?
• How much is ultimately collected from the payer and patient?
• Is the test included in a case rate?
• Are there diagnosis, medical necessity, or frequency restrictions?
• What percentage of claims are denied or adjusted?

Step 3: Evaluate the proposed test

For the exact product and intended workflow, confirm:

• Is the proposed use consistent with the product’s FDA labeling?
• What CLIA and state requirements apply?
• Is the test clinically suitable for your patient population?
• What billing code, if any, accurately describes the service performed?
• Will each major payer cover and separately reimburse it?
• Are there contract restrictions or patient financial responsibility rules?

Request written clarification from the payer when its policy is unclear, and keep a record of the question, product details, and response.

Step 4: Compare contribution per test

A practical starting point is:

Actual test-related collections − direct testing costs = estimated contribution per test

For case-rate contracts, include the relevant contract payment in a broader visit-level analysis. Do not count the same case-rate payment as additional revenue for each test.

Also review scenarios where an initial test leads to another test or follow-up. The lowest kit cost may not yield the best overall result.

Could a hybrid approach work?

For some practices, the answer may be a combination of workflows rather than a single test for every situation.

For example, a practice might:

• Continue to use an appropriate professional point-of-care test when a provider determines it is needed.
• Document and consider a patient’s independently obtained home test result during a visit.
• Offer guidance to patients who choose to test themselves at home.
• Evaluate different professional antigen and molecular tests based on clinical need, payer mix, and total cost.

Any workflow involving a home-use product at the clinic should first be reviewed for the exact product’s intended use and applicable requirements. Practices should also confirm that any patient charge is permitted by payer contracts and law, communicated in advance, and supported by the service provided.

Frequently asked questions

Can an urgent care bill insurance for a patient’s home test?

A practice should not bill for a clinic-performed laboratory test that it did not perform. A provider may consider and document a patient-reported home result as part of the clinical assessment; the visit itself may be billable when supported by the services provided and payer requirements.

Can urgent care bill for a home test performed by clinic staff?

Do not assume that a home-use test is billable as a professional point-of-care test. First determine whether the exact product and proposed use are permitted, what CLIA requirements apply, and whether the service meets the payer’s coding and coverage rules.

Are 4-in-1 home tests as accurate as CLIA-waived clinic tests?

It depends on the specific products and methods being compared. A clinic antigen test is not automatically more accurate than a home antigen test. Molecular tests generally have higher sensitivity than antigen tests for respiratory viruses. Practices should compare performance data for each target and avoid relying solely on percentages from different studies.

Is the cheapest test always the best choice under a case-rate contract?

Not necessarily. If testing is included in the case rate, a lower-cost product may reduce supply expense, but the clinic must still evaluate intended use, clinical performance, labor, quality control, and possible repeat-testing costs.

Does a four-in-one test mean the clinic can bill four separate tests?

Not automatically. Coding depends on the actual test, method, applicable code descriptors, and payer rules. The number of targets alone does not determine how many services can be billed.

Should a clinic switch tests before respiratory season?

A pre-season review can be useful, but the decision should follow a documented clinical, compliance, and financial assessment. Purchasing a lower-cost kit without confirming how it can be used and paid for may create an avoidable problem during your busiest season.

Make the decision with the full picture in view

Lower-cost home tests may look attractive to urgent care operators managing rising expenses. But if a clinic saves on supplies while losing separate reimbursement—or uses a product outside its intended workflow—the apparent savings can quickly disappear.

Start with the exact test and how the clinic proposes to use it. Then evaluate clinical performance, CLIA and state requirements, payer coverage, contract terms, and actual collected revenue. The strongest decision supports both patient care and the financial health of the practice.

Need help reviewing your urgent care testing workflows or revenue cycle performance? Connect with UrgentIQ at Sales@urgentiq.com to discuss how our team can help your practice evaluate its operational and billing processes.

‍